BioPharma Today

Coming In Monday's "The Pink Sheet" DAILY -- Avastin Moves Toward Ovarian Cancer Indication

Roche/Genentech’s Avastin takes another step forward toward an indication in ovarian cancer with the July 2 release of positive topline results from a second Phase III study showing an undisclosed benefit for progression free survival.

Latest News From "The Pink Sheet" DAILY - BMS Ends Deal With Exelixis

Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out

Coming In Tuesday's "The Pink Sheet" DAILY - DoJ, State AGs Call For Second Circuit To Rehear Cipro Case

ImmunoGen presents data at the American Society of Clinical Oncology's annual meeting on one of its growing number of internal compounds, IMGN388, in early development against solid tumors. The antibody conjugate company is building on positive results with trastuzumab-DM1, the Herceptin-based hybrid it built for Roche.

Latest News From "The Pink Sheet" DAILY - Ipilimumab, Crizotinib Study Results Unveiled At ASCO

Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight

Coming In Monday's "The Pink Sheet" DAILY - Is An FDA Approval Of Provenge For Prostate Cancer Around The Corner?

The European Court of Justice handed generics firms a victory on Thursday when it ruled that UK doctors could legally be incentivized to prescribe cheaper drugs.

Latest News from "The Pink Sheet" DAILY - GSK Doubles Up With Regulus

Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon

Watson's own citizen petitions blocking generics won't be an obstacle, company says.   read more

Coming in Monday's "The Pink Sheet" DAILY

In the first of a two-part interview, “The Pink Sheet” DAILY talks with King Pharmaceuticals CEO Brian Markison and Chief Scientific Officer Eric Carter about the company’s hopes for a wave of new drug formulations to treat chronic pain with lower abuse potential.

China Will Issue New Fast-Track Procedure For Drug Registration: CDE Official

Full article reprinted from "PharmAsia News" November 19, 2008

Read about why China's State FDA will launch a new fast-track mechanism by year end called the special approval procedure for drug registration to accelerate drug registration...